Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Yee Chao"'
Autor:
T. Ungtrakul, Yee Chao, L. Chong, Suebpong Tanasanvimon, Ursula Wiedermann, A. Sookprasert, L.-Y. Bai, Thomas Yau, A. Good, Chaiyut Charoentum, J. Maneechavakajorn, M. Maglakelidzde, Arunee Dechaphunkul, W. Arpornwirat, C.-J. Yen, I. Bulat, Christoph C. Zielinski, N. Ede, Wen-Chi Chou, E. Garner-Spitzer
Publikováno v:
Annals of Oncology. 30:v495-v496
Background HER2/neu is overexpressed in 15-25% of gastric cancer patients and associated with poor prognosis. Treatment with recombinant monoclonal Abs against HER2/neu is effective yet alternatives are needed due to cost and global availability issu
Autor:
Narikazu Boku, L. Evesque, A. McGinn, Lucjan Wyrwicz, Y-K Kang, A. Kryzhanivska, Min-Hee Ryu, Yee Chao, N. Sankar, Ian Chau, Wonyoung Kang, Jong Gwang Kim, K.-W. Lee, A. Takashima, Michael Schenker, Stefano Cascinu, M. Di Bartolomeo, V. Vladimirov, Harry H. Yoon, Sang Cheul Oh
Publikováno v:
Annals of Oncology. 30:v877-v878
Background Rivoceranib is an oral, selective tyrosine kinase inhibitor of VEGFR-2 with demonstrated efficacy for gastric cancer in China. ANGEL was a global phase III study to evaluate the efficacy and safety of rivoceranib in gastric cancer. Methods
Autor:
Alma Nielsen, Y. Zhang, C. Liu, S. Yang, Z. Shen, X. Wu, Yee Chao, J. Wang, M. Quiroz, Jayesh Desai
Publikováno v:
Annals of Oncology. 31:S300
Autor:
S.P. Choo, Thomas Yau, Y H Kim, Jaclyn Neely, Yee Chao, Yun Shen, M. Ikeda, H.Y. Lim, Y. Kang, Ming-Mo Hou, Marina Tschaika, Masatoshi Kudo, Tae-You Kim, C.-H. Hsu
Publikováno v:
Annals of Oncology. 31:233
Autor:
A-L Cheng, Marcelo Garrido, Amit S. Kulkarni, Masatoshi Kudo, Erluo Chen, Thomas Yau, Josephine M. Norquist, Richard S. Finn, Valeriy Breder, Sheng-Ju Chan, Yee Chao, Baek-Yeol Ryoo, Andrew X. Zhu, Sadahisa Ogasawara, H. Y. Lim, Bruno Daniele, Philippe Merle, Julien Edeline, Abby B. Siegel, Mohamed Bouattour
Publikováno v:
Annals of Oncology. 30:v256
Background KEYNOTE-240 (ClinicalTrials.gov: NCT02702401) is a double-blind, randomized, placebo-controlled, phase 3 trial that evaluated pembro 200 mg every 3 weeks compared with BSC in pts with advanced HCC who were previously systemically treated.
Autor:
Noelyn Anne Hung, Yee Chao, D. Kramer, C.-T. Hung, M-F R Kwan, David M. Cutler, Laura LaNiel Tenner, M.-H. Chen
Publikováno v:
Annals of Oncology. 30:v308
Background Oraxol consists of oral paclitaxel administered with the novel P-glycoprotein inhibitor HM30181A which enables the oral absorption of paclitaxel. Ramucirumab (RAM) + intravenous paclitaxel is FDA approved 2nd line treatment of gastric canc
Autor:
Scot Ebbinghaus, Marcelo Garrido, Abby B. Siegel, Jennifer J. Knox, Mohamed Bouattour, Andrew X. Zhu, Valeriy Breder, Richard S. Finn, Yee Chao, Sadahisa Ogasawara, H. Y. Lim, Stephen L. Chan, Baek-Yeol Ryoo, A-L Cheng, Terrence M. Yau, Erluo Chen, Philippe Merle, Julien Edeline, Bruno Daniele, Masatoshi Kudo
Publikováno v:
Publons
Autor:
Andrew F. Hill, Kiheon Lee, C-C. Lin, Chang-Hsien Lu, Jayesh Desai, Michael Friedlander, Yee Chao, J. Hou, Michael B. Jameson, Ben Markman, John Wu, C.-J. Yen, Bhumsuk Keam, Kun-Ming Rau, Y-K Kang, Michael Millward, Ming-Mo Hou, Jung-Gon Lee, Lisa G. Horvath, Sanjeev Deva
Publikováno v:
Annals of Oncology. 29:x24-x25
Autor:
Hyun Cheol Chung, Kentaro Yamazaki, Kei Muro, Yee Chao, Gu Mi, Rebecca Cheng, Mauro Orlando, Jin-Yuan Shih, Chia Jui Yen, Y. Zhang, Joohyuk Sohn, Keun Wook Lee, S.-W. Kim, T.W. Kim, Polina Binder, Masatoshi Kudo
Publikováno v:
Annals of Oncology. 27
Autor:
L. Chong, T. Ungtrakul, W. Lausoontornsiri, Yee Chao, Thomas Yau, C. Charoetum, Wen-Chi Chou, M. Maglakelidze, A. Good, S. Tanasanvimon, J. Maneechavakajon, Chia Jui Yen, N. Ede, W. Arpornwirat, Li Yuan Bai, I. Bulat, Herbert H. Loong
Publikováno v:
Annals of Oncology. 30:iv123
Background HER2/neu is overexpressed in 15% - 25% of gastric cancers. IMU-131 is a B-cell peptide vaccine composed of 3 epitopes of the extracellular domain of HER2/neu. Antibodies against IMU-131 peptides elicit antitumor activity in vitro and a pha